The FDA's assessment of two drugs for chronic weight management.
Food and Drug Administration, Silver Spring, MD, USA.
Eric
E
Colman
Julie
J
Golden
Mary
M
Roberts
Amy
A
Egan
Joyce
J
Weaver
Curtis
C
Rosebraugh
D000014:Abnormalities, Drug-Induced; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001552:Benzazepines / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D017277:Drug Approval; D004338:Drug Combinations; D005260:Female; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D010645:Phentermine / Q000627:therapeutic use*; D011247:Pregnancy; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D000077236:Topiramate; D014481:United States; D014486:United States Food and Drug Administration; D015431:Weight Loss / Q000187:drug effects
D019440:Anti-Obesity Agents; D001552:Benzazepines; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D017366:Serotonin Receptor Agonists; D000077236:Topiramate; D005632:Fructose; C506658:lorcaserin; D010645:Phentermine